Aripiprazole: An overview of a novel antipsychotic

Psychiatria Danubina

Volumn 17, Issue 1-2, 2005, Pages 67-75

  Uzun, Suzana ^a   Kozumplik, Oliver ^a   Mimica, Ninoslav ^a   Folnegović Šmalc, Vera ^a  

^a Psychiatric Hospital Vrap e   (Croatia)

Author keywords

Adverse events; Aripiprazole; Clinical trials; Dosage; Drug interactions; Efficacy; Pharmacodynamics; Pharmacokinetics; Pharmacotherapy; Therapy

Indexed keywords

ALPHA 1 ADRENERGIC RECEPTOR; ARIPIPRAZOLE; CARBAMAZEPINE; DEHYDROARIPIPRAZOLE; DEXTROMETHORPHAN; DOPAMINE 2 RECEPTOR; DOPAMINE 3 RECEPTOR; DRUG METABOLITE; DRUG METABOLIZING ENZYME; ERYTHROMYCIN; FAMOTIDINE; FERRIC OXIDE; FLUOXETINE; HALOPERIDOL; HISTAMINE H1 RECEPTOR; HYDROXYPROPYLCELLULOSE; ITRACONAZOLE; KETOCONAZOLE; LACTOSE; LITHIUM; MAGNESIUM STEARATE; MICROCRYSTALLINE CELLULOSE; OMEPRAZOLE; PAROXETINE; QUINIDINE; SEROTONIN 1A RECEPTOR; STARCH; UNCLASSIFIED DRUG; UNINDEXED DRUG; VALPROIC ACID; WARFARIN;

ACCIDENT; ALZHEIMER DISEASE; AREA UNDER THE CURVE; BINDING AFFINITY; BIOEQUIVALENCE; BIPOLAR I DISORDER; BIPOLAR MANIA; BRONCHITIS; CLINICAL TRIAL; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG ELIMINATION; DRUG FORMULATION; DRUG HALF LIFE; DRUG METABOLISM; DRUG PROTEIN BINDING; DRUG RECEPTOR BINDING; DRUG SAFETY; DRUG STRUCTURE; FOOD DRUG INTERACTION; HUMAN; INJURY; MANIA; MEAL; MULTIPLE DRUG DOSE; PSYCHOSIS; REVIEW; SCHIZOPHRENIA; SOMNOLENCE; STEADY STATE;

ALZHEIMER DISEASE; ANTIPSYCHOTIC AGENTS; BRAIN; CLINICAL TRIALS; HALF-LIFE; HUMANS; METABOLIC CLEARANCE RATE; PIPERAZINES; PSYCHOTIC DISORDERS; QUINOLONES; RECEPTORS, NEUROTRANSMITTER; TREATMENT OUTCOME;

EID: 23644446440     PISSN: 03535053     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (32)

1. Approved Ability (aripiprazole) US Package Insert, 2002.
2. Argo TR, Carnahan RM, Perry PJ. Aripiprazole, a novel atypical antipsychotic drug. Pharmacotherapy 2004;24(2):212-28.
3. Baptista T, Zarate J, Joober R, Colasante C, Beaulieu S, Paez X, Hernandez L. Drug induced weight gain, an impediment to successful pharmacotherapy: focus on antipsychotics. Curr Drug Targets 2004;5(3):279-99.
4. Bowles TM, Levin GM. Aripiprazole: a new atypical antipsychotic drug. Ann Pharmacother 2003;37(5):687-94.
5. Buckley PF. Aripiprazole: efficacy and tolerability profile of a novel-acting atypical antipsychotic. Drugs Today (Barc) 2003;39(2):145-51.
6. Burris K. Binding of BMS-337039 (aripiprazole) and reference antipsychotics to histaminergic and serotonergic receptors. 2001 BMS Document Control No. 920010832.
7. Burris KD, Molski TF, Xu C, Ryan E, Tottori K, Kikuchi T, Yocca FD, Molinoff PB. Aripiprazole, a novel antipsychotic, is a high-affinity partial agonist at human dopamine D2 receptors. J Pharmacol Exp Ther 2002;302(1):381-9.
8. DeLeon A, Patel NC, Crismon ML. Aripiprazole: a comprehensive review of its pharmacology, clinical efficacy, and tolerability. Clin Ther 2004;26(5):649-66.
9. El-Sayeh HG, Morganti C. Aripiprazole for schizophrenia. Cochrane Database Syst Rev. 2004(2):CD004578.
10. Fischer B, Davids E, Gastpar M. Aripiprazole: a new atypical antipsychotic drug. Fortschr Neurol Psychiatr. 2004;72(9):497-502.
11. Folnegović-Šmalc V, Jukić V, Kozumplik O, Uzun S and Mimica N. Side effect profile of atypical antipsychotic medications and comparison to conventional antipsychotics: review. Soc psihijatrija 2003:31;19-24.
12. Goodnick PJ, Jerry J. Aripiprazole: profile on efficacy and safety. Expert Opin Pharmacother 2002;3:1773-81.
13. Hirose T. Affinity of aripiprazole (OPC-14597) metabolites of dopamine D3 receptors. Otsuka report No. 013290. 2000 BMS Document Control No. 920008550.
14. Kane JM, Carson WH, Saha AR, McQuade RD, Ingenito GG, Zimbroff DL, Ali MW. Efficacy and safety of aripiprazole and haloperidol versus placebo in patients with schizophrenia and schizoaffective disorder. J Clin Psychiatry 2002;63(9):763-71.
15. Kasper S, Lerman MN, McQuade RD, Saha A, Carson WH, Ali M, Archibald D, Ingenito G, Marcus R, Pigott T. Efficacy and safety of aripiprazole vs. haloperidol for long-term maintenance treatment following acute relapse of schizophrenia. Int J Neuropsychopharmacol 2003;6(4):325-37.
16. Keck PE Jr, Marcus R, Tourkodimitris S, Ali M, Liebeskind A, Saha A, Ingenito G; Aripiprazole Study Group. A placebo-controlled, double-blind study of the efficacy and safety of aripiprazole in patients with acute bipolar mania. Am J Psychiatry 2003;160(9):1651-8.
17. Kinon BJ, Ahl J, Stauffer VL, Hill AL, Buckley PF. Dose response and atypical antipsychotics in schizophrenia. CNS Drugs 2004; 18(9):597-616.
18. Marder SR, McQuade RD, Stock E, Kaplita S, Marcus R, Safferman AZ, Saha A, Ali M, Iwamoto T. Aripiprazole in the treatment of schizophrenia: safety and tolerability in short-term, placebo-controlled trials. Schizophr Res 2003;61(2-3):123-36.
19. McGavin JK, Goa KL. Aripiprazole. CNS Drugs 2002;16(11):779-86.
20. Melkersson K, Dahl ML. Adverse metabolic effects associated with atypical antipsychotics: literature review and clinical implications. Drugs. 2004;64(7):701-23.
21. Mimica N. Novi antipsihotici i sigurnost pri liječenju. Psychiatria Danubina 2003;15(Supp. 1): S33-S36.
22. Otsuka Pharmaceutical Co, Bristol Myers Squibb Pharmaceutical. Investigator brochure. Aripiprazole. Bristol Myers Squibb Pharmaceutical Research Institute 2003.
23. Ozdemir V, Fourie J, Ozdener F. Aripiprazole (Otsuka Pharmaceutical Co). Curr Opin Investig Drugs 2002;3:113-20.
24. Pickar D 1995 Prospect for pharmacotherapy of schizophrenia. Lancet 345: 557-62.
25. Potkin SG, Saha AR, Kujawa MJ, Carson WH, Ali M, Stock E, Stringfellow J, Ingenito G, Marder SR. Aripiprazole, an antipsychotic with a novel mechanism of action, and risperidone vs placebo in patients with schizophrenia and schizoaffective disorder. Arch Gen Psychiatry 2003;60(7):681-90.
26. Sebastian CS, Glazer W, Buckley PF. Naturalistic studies of second generation antipsychotics in the treatment of schizophrenia. Curr Med Chem 2004;11(3):329-42.
27. Sprague DA, Loewen PS, Raymond CB. Selection of atypical antipsychotics for the management of schizophrenia. Ann Pharmacother 2004;38(2):313-9.
28. Stahl SM, Grady MM. A critical review of atypical antipsychotic utilization: comparing monotherapy with polypharmacy and augmentation. Curr Med Chem 2004;11(3):313-27.
29. Tamminga CA. Similarities and differences among antipsychotics. J Clin Psychiatry. 2003;64(17):7-10.
30. Winans E. Aripiprazole. Am J Health Syst Pharm 2003;60(23):2437-45.
31. Wolfe JM, Ali MW. Multiple dose tolerability and pharmacokinetic study of titrated doses of OPC-14597 in healthy male volunteers. (Study No. 31-93-204). Otsuka Maryland Research Institute. 1996. BMS Document Control No. 920002653.
32. Wolfe JM, Hayden DM. Multiple ascending dose tolerability and pharmacokinetic study of OPC-14597 in healthy young male volunteers (Study No. 31-93-201). Otsuka Maryland Research Institute. 1995. BMS Document Control No. 920002236.